Patents by Inventor Ian Popoff

Ian Popoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of p38 mitogen activated protein kinase expression
    Patent number: 7981868
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: July 19, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie, Susan M. Freier, Ian Popoff, James G. Karras
  • Antisense Modulation of P38 Mitogen Activated Protein Kinase Expression
    Publication number: 20080194503
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.
    Type: Application
    Filed: August 12, 2004
    Publication date: August 14, 2008
    Inventors: Brett P. Monia, Kenneth W. Dobie, Susan M. Freier, Ian Popoff, Wai Shiu Fred Wong, James G. Karras
  • Modulation of SOCS-3 expression
    Publication number: 20070021367
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided.
    Type: Application
    Filed: August 17, 2006
    Publication date: January 25, 2007
    Inventors: Ian Popoff, Susan Freier, Kenneth Dobie
  • Antisense modulation of CD40 ligand expression
    Publication number: 20060160758
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.
    Type: Application
    Filed: January 20, 2005
    Publication date: July 20, 2006
    Inventors: C. Bennett, Susan Freier, Brenda Baker, Brett Monia, Nicholas Dean, Hong Zhang, Susan Murray, Lex Cowsert, Madeline Butler, Robert McKay, Donna Ward, William Gaarde, Ian Popoff, Jacqueline Wyatt, Andrew Watt
  • Antisense modulation of dual specific phosphatase 5 expression
    Publication number: 20050197309
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of diseases associated with expression of dual specific phosphatase 5 are provided.
    Type: Application
    Filed: January 14, 2005
    Publication date: September 8, 2005
    Inventors: C. Bennett, Brett Monia, Susan Freier, Christopher Mirabelli, Ian Popoff, Jacqueline Wyatt, Andrew Watt, Kenneth Dobie
  • Antisense oligonucleotides and RNA-interfering molecules targeting PAK4
    Publication number: 20050191672
    Abstract: Compositions and methods for modulating the expression of the serine/threonine kinase PAK4 are provided. In particular, the invention relates to antisense compounds, particularly oligonucleotides and double-stranded RNA molecules, which specifically hybridize to nucleic acid molecules encoding PAK4. The oligonucleotides and RNA molecules decrease or inhibit PAK4 expression and thus, can be used in target identification and/or validation, to examine PAK4 pathways and the cellular effects of PAK4 expression, and to diagnose and/or treat abnormal cell growth or inflammation associated with PAK4 expression.
    Type: Application
    Filed: January 27, 2005
    Publication date: September 1, 2005
    Inventors: Ian Popoff, Todd Van Arsdale
  • Compositions and their uses directed to cell growth and maintenance proteins
    Publication number: 20050186594
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.
    Type: Application
    Filed: December 17, 2004
    Publication date: August 25, 2005
    Inventors: C. Bennett, Susan Freier, Nicholas Dean, Ian Popoff, Brett Monia, Donna Ward, Ming-Yi Chiang, Ravi Jain, Kenneth Dobie
  • Antisense modulation of damage-specific DNA binding protein 1, p127 expression
    Patent number: 6855700
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 1, p127. Methods of using these compounds for modulation of Damage-specific DNA binding protein 1, p127 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 1, p127 are provided.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: February 15, 2005
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense modulation of e2f transcription factor 2 expression
    Publication number: 20040048818
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 2. Methods of using these compounds for modulation of E2F transcription factor 2 expression and for treatment of diseases associated with expression of E2F transcription factor 2 provided.
    Type: Application
    Filed: August 25, 2003
    Publication date: March 11, 2004
    Inventors: Ian Popoff, Jacqueline R. Wyatt
  • Antisense modulation of PTPN2 expression
    Patent number: 6485974
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN2. Methods of using these compounds for modulation of PTPN2 expression and for treatment of diseases associated with expression of PTPN2 are provided.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: November 26, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Ian Popoff
  • Antisense modulation of PARP expression
    Patent number: 6451602
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of human PARP. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human PARP. Methods of using these compounds for modulation of human PARP expression and for treatment of diseases associated with expression of human PARP are provided.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: September 17, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Lex M. Cowsert
  • Antisense modulation of damage-specific DNA binding protein 1, p127 expression
    Publication number: 20020103146
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 1, p127. Methods of using these compounds for modulation of Damage-specific DNA binding protein 1, p127 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 1, p127 are provided.
    Type: Application
    Filed: December 6, 2000
    Publication date: August 1, 2002
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense modulation of damage-specific DNA binding protein 2, p48 expression
    Patent number: 6379960
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 2, p48. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 2, p48. Methods of using these compounds for modulation of Damage-specific DNA binding protein 2, p48 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 2, p48 are provided.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: April 30, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense inhibition of e2f transcription factor 1 expression
    Patent number: 6187587
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Vickie L. Brown-Driver, Lex M. Cowsert
  • Antisense inhibition of E2F transcription factor 3 expression
    Patent number: 6165791
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt